BACKGROUND: Trisomies 13, 18, and 21 account for the majority of chromosomal aneuploidies detected in prenatal diagnosis. Diagnosis of these trisomies relies mainly on karyotype analysis. Several molecular methods have been developed for trisomy detection, but performance or throughput limitations of these methods currently constrain their use in routine testing.
accounting for the majority of numerical chromosome alterations other than the sex chromosomes (1 ) . Prenatal diagnosis of trisomy is typically performed through karyotyping. Because intact fetal cells are required, this cell culture-based protocol often takes 13 to 14 days and occasionally can be affected by culture failure and external contamination, thus lowering its suitability for high-throughput testing. The method also causes undesirable distress to the pregnancy. These drawbacks are partially overcome with fluorescence in situ hybridization (FISH), 3 which is faster, does not require cell culture, and has a lower risk of maternal cell contamination (2 ) . FISH, however, is costly, is labor intensive, and requires intact cells and human expertise. It is currently applicable only to cases with ambiguous ultrasonographic findings.
To address these problems, investigators have developed PCR-based molecular methods that are characterized by the rapid acquisition of results and objective decision-making (3 ) . Quantitative fluorescence PCR is the most widely used PCR method, and its clinical usefulness has been assessed in many studies (4 -11 ) . The major drawback of this technique, however, is that informative polymorphisms found to be optimal in one human population may be ineffective in another (12 ) . Real-time quantitative PCR (rtPCR), which relies on the direct quantification of chromosomes rather than on polymorphisms (13 ) , could be applicable to all populations. This approach is particularly attractive in clinical practice because of its short turnaround time, easy automation, and avoidance of carryover contamination. Unfortunately, unambiguous discrimination between 2 and 3 copies of chromosomes, as required for aneuploidy analysis, has reached or surpassed the resolution limit of rtPCR. Consequently, even subtly biased amplification of loci on different chromosomes may produce ambiguous results. rtPCR of singlenucleotide polymorphisms (SNPs) followed by melting curve analysis with the LightCycler technology has also been proposed for estimating chromosome numbers in trisomy 21 detection (14 ) ; however, this approach requires the selection of multiple SNP markers to produce an informative result. Consequently, determination of the heterozygosity of various SNPs is necessary for different populations (15 ) .
Multiplex ligation-dependent probe amplification (MLPA), a method with an excellent ability to assess chromosome dosage, is being applied to an increasing variety of diseases involving copy number variations (CNVs), including aneuploidy analysis (12, 16 -19 ) . The success of MLPA in aneuploidy analysis is due to a probe-amplification strategy that allows improved precision of quantification compared with template amplification-based PCR. Two technical issues remain to be solved, however. One is that the long hybridization probes used for MLPA need to be prepared via phage M13 cloning rather than through chemical synthesis of short DNA oligonucleotides. The other issue is the use of electrophoresis for product analysis, which makes the method costly and vulnerable to carryover contamination.
We present the performance of a novel approach, in which MLPA and rtPCR are combined to resolve many of the problems described above. This method, called MLPA-based rtPCR (MLPA/rtPCR), takes advantage of both the accuracy of MLPA and the simplicity of rtPCR in quantification. MLPA/rtPCR reproducibly detects cases of trisomy 13, 18, and 21 in a single reaction. Moreover, the consistency and sensitivity of the method to detect mosaic samples eliminates problems of maternal blood contamination in prenatal diagnosis, a result that might have implications for noninvasive prenatal diagnosis with maternal blood samples.
Materials and Methods

SAMPLES
Trisomy samples of fetal blood diagnosed as aneuploidy were obtained from the Department of Genetics Laboratory, Maternal and Child Health Hospital of Xiamen. Samples of peripheral blood from healthy blood donors were provided by the Blood Centre of Xiamen. The Research Ethics Committee of Xiamen University approved the study protocol. All samples were coded, and the code numbers were known only to the technician who collected and coded the samples. A total of 144 coded samples (including 32 cases of trisomy 21, 11 cases of trisomy 18, 1 case of trisomy 13, and 100 unaffected controls) were tested. Genomic DNA was extracted from blood samples with the DNeasy Blood & Tissue Kit (Qiagen). The concentration of extracted genomic DNA was determined by measuring the UV absorbance at 260 nm with the ND-1000 NanoDrop UV-Vis spectrophotometer (Thermo Scientific) and was adjusted to 20 ng/L before use.
PRIMERS AND PROBES
In MLPA/rtPCR, the primer pair used for rtPCR detection was the same as the universal primer pair used in the SALSA MLPA kit P095 Aneuploidy (MRCHolland). The hybridization probes for chromosomes 13, 18, and 21 were modified from the original probemix of the P095 kit (see Fig. 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol56/issue9). Specifically, the stuffer fragment in each of the phage M13-derived long hybridization probes was replaced with a sequence for detection probe binding in the rtPCR. Such a sequence is common to all 8 hybridization probes specific for 1 type of chromosome, but it varies with the hybridization probes for different types of chromosomes. According to this design, the hybridization probe size was Ͻ80 nucleotides. Chemically synthesized oligonucleotides of this size with the quality needed for this application are commercially available. We used a displacing probe as the detection probe for rtPCR because of its extremely low background. The displacing probe, a partially double-stranded probe composed of a longer fluorophore-labeled probe and a shorter quencher-labeled probe, functions as the fluorogenic probe for rtPCR detection (20 ) . Because 3 chromosomes were detected, the final detection system was a 4-color rtPCR that included 1 primer pair and 3 detection probes. The detection probes for chromosome 21 were labeled with 6-carboxy-X-rhodamine (ROX), the detection probes for chromosome 18 were labeled with 6-carboxyfluorescein (FAM), and the detection probes for chromosome 13 were labeled with hexachloro-6-carboxyfluorescein (HEX). Cyanine dye Cy5 was used as the calibration dye. The sequences for the primers, hybridization probes, and detection probes are available in Table 1 in the online Data Supplement.
MLPA/rtPCR PROTOCOL
MLPA/rtPCR with the MRC-Holland P095 Aneuploidy kit included 3 steps: hybridization, ligation, and rtPCR. In brief, 5.0 L of genomic DNA was denatured for 5 min at 98°C. Then, 3.0 L of hybridization buffer (consisting of 1.5 L of MLPA buffer and 1.5 L of hybridization probemix) was added after the DNA had cooled to 25°C. The mixture was incubated for 1 min at 95°C and then for 16 h at 60°C. After hybridization, the mixture was cooled to 54°C; 32 L of ligase buffer mix was added and mixed well by pipetting up and down. The mixture was then incubated for 15 min at 54°C, followed by 5 min at 98°C and a hold at 4°C. 
DATA ANALYSIS
MLPA/rtPCR produced 3 amplification curves for each sample, 1 each from the FAM, HEX, and ROX channels. Quantification cycle (C q ) values (see definition in the online Data Supplement) and fluorescence intensity (FI) values were acquired. To detect differences in C q values and FI values, we developed 2 data analysis methods. The ⌬C q method is based on calculating the difference between C q values, which is given by: ⌬C qx ϭ (C qy ϩ C qz )/2 Ϫ C qx , where x, y, and z indicate the 3 respective fluorescence channels. The ⌬FI method is based on calculating the difference between FI values, which is given by:
Derivations of these equations can be found in the online Data Supplement. Statistical analyses were performed with OriginPro 7.5 software (OriginLab).
Results
With MLPA/rtPCR, each chromosome was assigned 8 pairs of hybridization probes that have a common detection probe-binding sequence but with each pair targeting a different region of the same chromosome. For the different chromosomes, the detection probebinding sequences of the hybridization probes were also different so that they could be detected by their corresponding detection probes with rtPCR. All of the hybridization probes shared the same primer-binding sequence. After sufficient hybridization, ligation of the 24 pairs of adjacent hybridization probes generated 24 ligated full-length hybridization probes that could be amplified exponentially by the PCR via a common primer pair. The chromosome aneuploidy status was determined by analyzing the 3 amplification curves of each sample. In theory, 4 possible results could be obtained for each sample. For a typical disomy condition (equal copy numbers of chromosomes 13, 18, and 21), the 3 amplification curves should overlap. For a trisomy 21, which has 3 copies of chromosome 21 and 2 copies each of chromosomes 13 and 18, we expected the ROX amplification curve to exhibit an increased FI and a smaller C q value, compared with the HEX and FAM curves. Similarly, for a trisomy 13 or 18 situation, the HEX or FAM amplification curve is expected to exhibit an increased FI and have a smaller C q value (Fig. 1) .
We analyzed 144 blinded clinical samples, among which the trisomy samples had previously been characterized by karyotype analysis. The unaffected samples were from healthy blood donors. The MLPA/ rtPCR results were first analyzed with the ⌬C q method. In this method, the plateau fluorescence of the amplification curve was divided into 10 equal segments, each of which was defined as a particular threshold ( Fig. 2A ) from which ⌬C q values calculated in the 3 channels were acquired and compared. In the ROX channel, which determines the difference between chromosome 21 and the other chromosomes, a group of 32 samples had large ⌬C q values distinct from those of the other samples. These samples were designated as trisomy 21 (Fig. 3A) . In the FAM channel, which determines the difference between chromosome 18 and the other chromosomes, a group of 11 samples had larger ⌬C q values that were distinctly separated, depending on the threshold used, from those of the other samples. These samples were designated as trisomy 18. Similarly, in the HEX channel, which is for trisomy 13, 1 sample had a significantly larger ⌬C q than the others, and this sample was designated as trisomy 13. The other 100 samples were designated as unaffected samples.
To determine the threshold interval in which the trisomy samples could be separated from the unaffected samples, we averaged the ⌬C q values, calculated the deviation of each group of trisomy samples, and compared them with the unaffected samples over the entire threshold range. The results showed that no overlap occurred between the 2 groups between threshold 10 and threshold 70, regardless of whether the reference interval was set as "mean (SD)" or as "minimum to maximum," for both trisomy 21 (Fig.  3B , ROX column) and trisomy 18 (Fig. 3B, FAM column) . In the case of trisomy 13, the trend was visible, but statistical analysis was not reliable because of the small sample size (Fig. 3B, HEX column) . To determine the threshold at which the best discrimination between trisomy and unaffected samples was achieved, we calculated the F statistics of the ⌬C q by one-way ANOVA (21 ) . By plotting the F statistics against the thresholds for each trisomy group and the unaffected samples, we observed that the largest differentiation between trisomy 21 and the unaffected samples occurred between thresholds 20 and 40, which were located within the exponential phase of amplification (Fig. 3C, ROX column) . Similar results were observed with samples of trisomy 18 (Fig. 3C , FAM column) and trisomy 13 (Fig. 3C, HEX column) .
To verify these results, we also analyzed the amplification curves with the vertical scanning strategy. FI values for 3 channels were collected every 2 cycles from the 24th to the 50th cycle (Fig. 2B) , and the corresponding 3 ⌬FI values were calculated and compared. As with the ⌬C q method, the ⌬FI approach also showed that trisomy cases and unaffected controls were segregated distinctly into separate groups (see Fig.  2A in the online Data Supplement). The sample assignment was in complete agreement with that of the ⌬C q method. Statistical analysis of both the trisomy samples and unaffected controls demonstrated no overlap between trisomy and control samples over a wide interval of cycle numbers, regardless of whether the reference interval was set as "mean (SD)" or "minimum to maximum" (see Fig. 2B in the online Data Supplement). By plotting F statistics (from one-way ANOVA of ⌬FI values) against cycle number for both the trisomy groups and the unaffected control group, we also achieved the largest differentiation within the exponential phase of amplification (see Fig. 2C in the online Data Supplement).
Comparing the MLPA/rtPCR results with those of the karyotype analysis showed complete concordance, because all trisomy and unaffected samples were iden- tified correctly. Thus, the MLPA/rtPCR method attained 100% sensitivity and 100% specificity when karyotyping was used as a reference. Considering the agreement between the 2 data analysis methods, we conclude that MLPA/rtPCR results could be analyzed by either the ⌬C q method or the ⌬FI method.
To explore the resolving power of the MLPA/ rtPCR method, we tested different ratios of trisomy samples and unaffected control samples. Samples containing 20% trisomic DNA (corresponding to a 1.1-fold change in chromosome dosage) could have their ⌬C q values differ significantly from those of the unaffected controls (P ϭ 0.00485). Samples containing 40% trisomic DNA (corresponding to a 1.2-fold change in chromosome dosage) were completely differentiated from the unaffected samples with no overlap (Fig. 4) , demonstrating that this method could unambiguously detect a change in chromosome dosage as small as 1.2-fold.
Finally, we investigated the effects of hybridization probe number, hybridization time, and template DNA quantity on the discrimination power of the MLPA/ rtPCR method. The results showed that 8 hybridization probes for 1 chromosome demonstrated substantially larger F values (one-way ANOVA) than 1 probe for 1 chromosome (Fig. 5A) . With respect to hybridization time, we observed that although 16 h was the recommended hybridization time for the MLPA protocol, 4 h of hybridization produced even better discrimination. Shorter hybridization times (e.g., 2 h or 1 h) lowered the discrimination power of the MLPA/ rtPCR (Fig. 5B) . The starting amount of DNA template also substantially influenced the discrimination power. F values increased with the amount of template DNA, with 10 ng DNA template being sufficient to provide statistically significant discrimination (P ϭ 0.00) (Fig. 5C ).
Discussion
The difficulty in discriminating a difference in chromosome dosage of 3 vs 2 has long hindered the development of high-throughput, user-friendly, and universal molecular diagnostics for trisomy. Although the literature has described an rtPCR-based method that can detect trisomy 21 (13 ) , it has limited resolution, which precludes its use in prenatal diagnosis. Rapid detection of aneuploidy (trisomy 21) by allele quantification combined with melting curve analysis of SNP loci, on the other hand, requires 6 SNP loci to provide informative data in 98% of the population (14, 15 ) . Consequently, trisomy diagnosis still relies on quantitative fluorescence PCR or MLPA, each of which is characterized by low throughput and expensive instrumentation, to deliver molecular information not achievable with current rtPCR-based analysis. Our data have demonstrated that MLPA/rtPCR could meet the demands of rapid and accurate prenatal diagnosis of aneuploidy. The aneuploidy status of chromosomes 13, 18, and 21 was assessed accurately and simultaneously in a single rtPCR. Because chemically synthesized oligonucleotides were used, the method was also easier to set up and less expensive than MLPA, which requires preparation of phage M13 DNA and post-PCR electrophoresis analysis.
One advantage of our MLPA/rtPCR method is its high reproducibility and accuracy in detecting trisomies. As demonstrated with the ⌬C q data analysis methods, no overlap between the trisomy and the unaffected samples was encountered within a wide interval of thresholds (from 10 to 70). We attribute such high discrimination to 2 factors. The first factor is the probe-amplification nature of MLPA/rtPCR, which substantially reduces the amplification bias induced by 
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direct amplification of the target. The quantification accuracy of target amplification, like the PCR, strongly depends on whether amplification efficiency varies with the primers. In contrast, the probe-amplification method involves a ligation step that generates probes with a universal primer-binding sequence, which is used as the target for the following amplifications with a common primer pair. Consequently, the MLPA/ rtPCR amplification efficiencies among differently ligated products can be equalized easily. The second factor is the use of multiple probes in the hybridization step. Theoretically, 1 hybridization probe should be sufficient to identify 1 chromosome; however, because of the wide distribution of CNVs in the human genome (22, 23 ) , variable hybridization efficiency, and biased amplification efficiency, single probe-based hybridization, ligation, and PCR detection may cause unpredictable and unavoidable errors. Such random errors can largely be eliminated via the use of multiple probes that yield a cumulative signal. For example, if 1 CNV occurs in 1 of the 8 probe targeting sites, the contribution of this CNV to the overall signal of that chromosome is 1 in 8, on average. Hybridization efficiency may vary among different probes, leading to varied amplification efficiency, which also can be reduced on average via the use of multiple hybridization probes. Indeed, 8 pairs of hybridization probes produced much better differentiation results than 1 pair of probes (Fig.  5A ). In contrast, single target-based methods of aneuploidy detection, such as rtPCR (13 ), homologous gene quantitative PCR (24 ) , and paralogous sequence quantification (25 ) , are all vulnerable to the existence of CNVs and variable hybridization efficiency. Another advantage of the MLPA/rtPCR method is the high resolution, which is critical in aneuploidy analyses involving chromosomal mosaicism and contamination with maternal blood. For a PCR with an amplification efficiency of 100%, a 2-fold difference in input DNA induces a 1-cycle difference in the rtPCR. A difference of 3 vs 2 in the quantity of input DNA induces a difference of 0.585 cycles. Such a small difference cannot be differentiated accurately with routine rtPCR methods. Our results have shown that the MLPA/rtPCR method can differentiate a dosage change of as little as 1.2-fold, which corresponds to a difference of 0.263 cycles. This level of resolution permits aneuploidy analysis in situations involving chromosomal mosaicism and maternal blood contamination.
Chromosomal mosaicism, the presence of 2 or more cell populations with different genotypes in a single individual, is a possible mechanism for intrauterine and postnatal survival in cases of trisomy 18 (26 -28 ) . The frequency of mosaicism is 100% in cases of trisomy 18 (28 ) , whereas the frequency of mosaicism is 20% to 33% in cases of trisomy 21 (28, 29 ) . Our results of a single distinct group of trisomy 21 cases but a scattered grouping of trisomy 18 cases (Fig. 3 ) reflect this fact, despite the differentiation of both trisomies from the unaffected samples.
The high resolution of MLPA/rtPCR may also find applications in noninvasive prenatal diagnosis that uses maternal blood. Although the data are not yet universally accepted, several studies have claimed 30%-40% enrichment of fetal DNA by suppressing the maternal DNA background (30, 31 ) . Lo et al. reported that the mean fetal DNA concentration in maternal plasma is 25.4 genome equivalents/mL (32 ) . To obtain 10 ng of plasma DNA with 40% of fetal origin requires 26 mL of plasma. This clinical barrier might be over- Mixed samples containing 20%, 30%, 40%, and 50% trisomic DNA were prepared by diluting trisomy 21 DNA with unaffected control DNA. The mixed samples (10 ng) were then analyzed with the MLPA/rtPCR assay. The ⌬C q value for each sample was acquired when the threshold was set at 30% of the plateau fluorescence. The line within each box denotes the median, the square within the box denotes the mean, the horizontal borders of each box denote the SD, and the whiskers denote the minimum and maximum. The dashed line indicates that the samples containing 40% trisomy 21 DNA and the unaffected control samples had no overlap in ⌬C q values. come in 2 ways. One way is to decrease the volume of the hybridization by 10-fold, so that 2.6 mL of plasma would be sufficient. The other is to increase the sensitivity of MLPA/rtPCR. For example, if 1.0 ng plasma DNA is sufficient for the MLPA/rtPCR analysis, then the plasma needed could be decreased by 10-fold. A recent study demonstrated that modifying 1 of the universal primers would allow the amount of template DNA needed for MLPA to be reduced to 1.6 ng/reaction (33 ) . If the 2 methods were combined, the volume of plasma needed for noninvasive prenatal diagnosis might be further reduced. The MLPA/rtPCR protocol takes nearly 2 days despite the adoption of rtPCR; however, ways exist to shorten the overall turnaround time. For example, 4-h and 16-h hybridizations provided similar discrimination (Fig. 5B) . We postulate that shorter hybridization probes may hybridize more readily with their target sequences than long probes. Additional shortening of the hybridization time is possible if the hybridization and ligation steps are further optimized by combining the hybridization and ligation into a single step through the use of a thermostable DNA ligase.
We note that because of the spectral overlap of fluorophores and the limited number of detection channels in an rtPCR thermocycler, the number of chromosomes that can be detected in a single reaction is limited. In this work, we detected 3 of 5 chromosomes covered by the MLPA aneuploidy kit; if chromosomes X and Y were to be included, 1 additional reaction would have to be used. We also note that our method, like MLPA, might miss cases of structural abnormalities, such as balanced translocations. Nevertheless, this drawback would not hinder the wide application of our method because trisomies of chromosomes 13, 18, and 21 and aneuploidies of chromosomes X and Y account for up to 99.9% of the diseaseassociated abnormalities (25 ) .
In summary, the MLPA/rtPCR method advances the diagnostic utility of both MLPA and rtPCR for aneuploidy analysis. The probe-amplification nature ensured the reliability of this method, and rtPCR detection significantly reduced post-PCR manipulations, time requirements, and carryover contamination. Furthermore, the high resolution of the MLPA/rtPCR method represents a critical step toward the development of noninvasive prenatal aneuploidy detection with maternal blood.
